Nimodipine Altan (Nimodipine)

Nimodipine blocks L‑type calcium channels on the smooth muscle of cerebral arteries. This inhibition reduces calcium‑mediated contraction, leading to selective dilation of brain vessels and a decrease in the likelihood and severity of vasospasm after hemorrhagic events.

The dosage of Nimodipine Altan is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. The prescribing information provides guidance, but the exact regimen must be individualized and documented by a qualified healthcare professional.

Safety data for Nimodipine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimodipine is a dihydropyridine calcium‑channel blocker that offers selective cerebral vasodilation, whereas other agents such as clazosentan target endothelin receptors. Nimodipine’s advantage lies in its well‑established efficacy for SAH‑related vasospasm and a relatively favorable safety profile when used under controlled conditions.

Store Nimodipine Altan at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and ensure that the vial is sealed until use to maintain sterility.

Nimodipine Altan is supplied for intravenous infusion. The medication is administered by a qualified healthcare professional in a hospital or clinical setting, following aseptic technique and the dosing instructions provided by the prescriber.

The most serious risks include severe hypotension, which can lead to syncope or organ hypoperfusion, and rare but potentially life‑threatening allergic reactions such as anaphylaxis. Continuous monitoring of blood pressure and signs of hypersensitivity is essential during treatment.

Patients with known hypersensitivity to nimodipine or any component of the formulation should avoid its use. Caution is also advised for individuals with severe hepatic impairment, uncontrolled hypotension, or those taking contraindicated strong CYP3A4 inhibitors without medical supervision.